ArticleTransfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine2021
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
Article in Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- COVID-19 convalescent plasma for B-cell depleted patients: a systematic review and individual patient data meta-analysis.Frontiers in medicine · 2025Article
- Article
- Effectiveness of Convalescent Plasma Therapy in COVID-19 Patients with Hematological Malignancies: A Systematic Review.Hematology reports · 2022Article
- SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2022Article
- COVID-19convalescent plasma use in the oncology and geriatric patients: Ethical aspects in transfusion medicine.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2022Article
- Article
- Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States.Transfusion · 2022Review
- Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?Frontiers in immunology · 2022Article
- Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks.Frontiers in immunology · 2022Article
- Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections.Clinical lymphoma, myeloma & leukemia · 2021Review
- Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment.Pharmaceutics · 2021Review
- Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2021Article
- Compassionate mesenchymal stem cell treatment in a severe COVID-19 patient: a case report.Croatian medical journal · 2021Article
- The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response.Current research in pharmacology and drug discovery · 2021Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe patients with hematological malignancies are a vulnerable group to COVID-19, due to the immunodeficiency resulting from the underlying disease and oncological treatment that significantly impair cellular and humoral immunity. Here we report on a beneficial impact of a passive immunotherapy with convalescent plasma to treat a prolonged, active COVID-19 infection in a patient with a history of nasopharyngeal diffuse large B-cell lymphoma treated with the therapy inducing substantial impairment of particularly humoral arm of immune system. The specific aim was to quantify SARS-CoV2 neutralizing antibodies in a patient plasma during the course of therapy. MATERIALS AND
methodsBesides the standard of care treatment and monitoring, neutralizing antibody titers in patient's serum samples, calibrated according to the First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human), were quantified in a time-dependent manner. During the immunotherapy period peripheral blood flow cytometry immunophenotyping was conducted to characterize lymphocyte subpopulations.
resultsThe waves of clinical improvements and worsening coincided with transfused neutralizing antibodies rises and drops in the patient's systemic circulation, proving their contribution in controlling the disease progress. Besides the patient's lack of own humoral immune system, immunophenotyping analysis revealed also the reduced level of helper T-lymphocytes and immune exhaustion of monocytes.
conclusionTherapeutic approach based on convalescent plasma transfusion transformed a prolonged, active COVID-19 infection into a manageable chronic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.